Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5457]

Camizestrant may be superior to fulvestrant in patients with hormone receptor...

Dr Mafalda Oliveira - Vall d’Hebron University Hospital, Barcelona, Spain

Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer ( Dr Mafalda Oliveira - Vall d’Hebron University Hospital, Barcelona, Spain )

An analysis of the worldwide utilisation of haematopoietic stem cell...

Dr Molly Tokaz - Fred Hutchinson Cancer Center, Seattle, USA

An analysis of the worldwide utilisation of haematopoietic stem cell transplantation for acute myeloid leukaemia ( Dr Molly Tokaz - Fred Hutchinson Cancer Center, Seattle, USA )

Opinion: Premature regulatory approval by the FDA

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Opinion: Premature regulatory approval by the FDA ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable...

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable...

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

Addition of platinum to standard neoadjuvant chemotherapy improves EFS in...

Dr Sudeep Gupta - Tata Memorial Centre, Mumbai, India

Addition of platinum to standard neoadjuvant chemotherapy improves EFS in patients with TNMBC ( Dr Sudeep Gupta - Tata Memorial Centre, Mumbai, India )

Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows...

Dr Emma Searle - University of Manchester, Manchester, UK

Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows promising results in patients with multiple myeloma ( Dr Emma Searle - University of Manchester, Manchester, UK )

Treatment decision guided by CTC count may improve long-term outcomes for mBC

Prof Jean-Yves Pierga - Institut Curie, Paris, France

Treatment decision guided by CTC count may improve long-term outcomes for mBC ( Prof Jean-Yves Pierga - Institut Curie, Paris, France )

The future of precision oncology

Dr Benedikt Westphalen - Comprehensive Cancer Center München, Munich, Germany

The future of precision oncology ( Dr Benedikt Westphalen - Comprehensive Cancer Center München, Munich, Germany )

The concept of pan-tumour therapeutics

Dr Benedikt Westphalen - Comprehensive Cancer Center München, Munich, Germany

The concept of pan-tumour therapeutics ( Dr Benedikt Westphalen - Comprehensive Cancer Center München, Munich, Germany )

Access to Oncology Medicines Coalition - The Medicines Patent Pool

Charles Gore - Medicines Patent Pool, Geneva, Switzerland

Access to Oncology Medicines Coalition - The Medicines Patent Pool ( Charles Gore - Medicines Patent Pool, Geneva, Switzerland )

Challenges and opportunities of integrative oncology as an effective tool to...

Dr Partha Basu - International Agency for Research on Cancer, Lyon, France

Challenges and opportunities of integrative oncology as an effective tool to enhance cancer prevention and treatment in LMICs. ( Dr Partha Basu - International Agency for Research on Cancer, Lyon, France )

More from ecancer